Efficacy and Safety of Cyclophosphamide Treatment in Severe Juvenile Dermatomyositis Shown by Marginal Structural Modeling

OBJECTIVE: In patients with severe or refractory juvenile dermatomyositis (DM), second‐line treatments may be required. Cyclophosphamide (CYC) is used to treat some connective tissue diseases, but evidence of its efficacy in juvenile DM is limited. This study was undertaken to describe clinical impr...

Descripción completa

Detalles Bibliográficos
Autores principales: Deakin, Claire T., Campanilho‐Marques, Raquel, Simou, Stefania, Moraitis, Elena, Wedderburn, Lucy R., Pullenayegum, Eleanor, Pilkington, Clarissa A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Pediatric Rheumatology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5947636/
https://www.ncbi.nlm.nih.gov/pubmed/29342499
http://dx.doi.org/10.1002/art.40418

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5947636/
https://www.ncbi.nlm.nih.gov/pubmed/29342499
http://dx.doi.org/10.1002/art.40418

Ejemplares similares